Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis

Liver International

Volumn 23, Issue 2, 2003, Pages 116-123

  Czaja, Albert J ^a   Carpenter, Herschel A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Pathogenic mechanisms; Plasma cells; Relapse

Indexed keywords

CORTICOSTEROID; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PLASMA CELL; PREDICTION; RELAPSE; REMISSION; SENSITIVITY ANALYSIS; BIOPSY; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; EVALUATION; FOLLOW UP; HOSPITALIZATION; LIVER; MIDDLE AGED; PATHOLOGY; PATIENT SATISFACTION; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME; UNITED STATES; WITHDRAWAL SYNDROME;

ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MINNESOTA; PATIENT SATISFACTION; PREDICTIVE VALUE OF TESTS; PREDNISONE; RECURRENCE; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0043288746     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2003.00810.x     Document Type: Article

References (46)

1. Soloway R D, Summerskill W H J, Baggenstoss A H, Geall M G, Gitnick G L, Elveback L R, Schoenfield L J. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
2. Czaja A J. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999; 57: 49-68.
3. Czaja A J, Ammon H V, Summerskill W H J. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518-23.
4. Czaja A J, Ludwig J, Baggenstoss A H, Wolf A. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981; 304: 5-9.
5. Hegarty J E, Nouri-Aria K T, Portmann B, Eddleston A L W F, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-9.
6. Czaja A J, Davis G L, Ludwig J, Taswell H F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-7.
7. Czaja A J, Wolf A M, Baggenstoss A H. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-92.
8. Czaja A J. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995; 40: 435-56.
9. McFarlane I G. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999; 53: 255-63.
10. Czaja A J. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 1224-31.
11. Lohr H, Manns M, Kyriatsoulis A, Lohse A W, Trautwein C, Meyer zum Buschenfelde K-H, Fleischer B. Clonal analysis of liver-infiltrating T-cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991; 84: 297-302.
12. Page A R, Condie R M, Good R A. Suppression of plasma cell hepatitis with 6-mercaptopurine. Am J Med 1964; 36: 200-13.
13. Cohen S, Ohta G, Singer E J, Popper H. Immunocytochemical study of gamma globulin in liver in hepatitis and postnecrotic cirrhosis. J Exp Med 1960; 11: 285-93.
14. Paronetto F, Rubin E, Popper H. Local formation of gamma-globulin in the diseased liver and its relation to hepatic necrosis. Laboratory Invest 1962; 11: 150-8.
15. Jensen D M, McFarlane I G, Portmann B S, Eddleston A L W F, Williams R. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 1978; 299: 1-7.
16. Cochrane A M G, Moussouros A, Thomson A D, Eddleston A L W F, Williams R. Antibody-dependent cell-mediated (K-cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet 1976; 1: 441-4.
17. Nouri-Aria K J, Hegarty J E, Alexander G J M, Eddleston A L W F, Williams R. Effect of corticosteroids on suppressor-cell activity in 'autoimmune' and viral chronic active hepatitis. N Engl J Med 1982; 307: 1301-4.
18. Bratts R, Linden M. Cytokine modulation by glucocorti-costeroids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10: 81-90.
19. Reichardt H M, Schutz G. Glucocorticoid signaling-multiple variations of a common theme. Mol Cell Endocrinol 1998; 146: 1-6.
20. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22.
21. Almawi W Y. Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol 2001; 2: 78-82.
22. Liblau R S, Singer S M, McDevitt H O. Th1 and Th2 CD4+ T-cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-8.
23. Johnson P J. Immunosuppressive drug mechanisms. In: McFarlane I G, Williams R, eds. Molecular Basis of Autoimmune Hepatitis. Austin: RG Landes, 1996: 177-91.
24. Alvarez F, Berg P A, Bianchi F B, Bianchi L, Burroughs A K, Cancado E L, Chapman R W. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
25. Czaja A J, Freese D K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
26. Czaja A J. Treatment of autoimmune hepatitis. Semin Liver Dis 2002; 22: 365-77.
27. Carpenter H A, Czaja A J. The role of histological evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002; 6: 685-705.
28. Czaja A J, Beaver S J, Shiels M T. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-9.
29. Czaja A J, Menon K V N, Carpenter H A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-7.
30. Summerskill W H J, Korman M G, Ammon H V, Baggenstoss A H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-83.
31. Czaja A J. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044-9.
32. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
33. Czaja A J, Carpenter H A. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-32.
34. Czaja A J, Carpenter H A. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997; 26: 459-66.
35. Soloway R D, Baggenstoss A H, Schoenfield L J, Summerskill W H J. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1975; 20: 1087-90.
36. Weiner H L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-14.
37. Bach J-F. Non-Th2 regulatory T-cell control of Th1 autoimmunity. Scand J Immunol 2001; 54: 21-9.
38. Al-Wabel A, Al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol 1993; 92: 902-8.
39. Lohr H F, Schaak J F, Gerken G, Fleischer B, Dienes H-P, Meyer zum Buschenfelde K-H. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T-lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994; 14: 161-6.
40. Schlaak J F, Lohr H, Gallati H, Meyer Zum Buschenfelde K-H, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T-cells of patients with autoimmune hepatitis. Clin Exp Immunol 1993; 94: 168-73.
41. Czaja A J, Sievers C, Zein N N. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci 2000; 45: 1028-35.
42. Vergani D, Choudhuri K, Bogdanos D P, Mieli-Vergani G. Autoimmune hepatitis-pathogenic mechanisms. Clin Dis Liver 2002; 6: 727-37.
43. McFarlane I G, Hegarty J E, McSorley C G, McFarlane B M, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954-6.
44. Czaja A J, Pfeifer K D, Decker R, Vallari A S. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733-40.
45. Czaja A J, Donaldson P T, Lohse A W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-9.
46. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi F B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721-6.